Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806928 | 0.84 | ALDH1A1 (0.48) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL2588266 | 0.84 | ALDH1A1 (0.73) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL4813888 | 0.83 | KMT2A (0.65) | ALDH1A1OPRD1OPRK1KMT2ALMNA | |
| SCHEMBL4812915 | 0.83 | ALDH1A1 (0.55) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL14704741 | 0.82 | ALDH1A1 (0.59) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL5240524 | 0.79 | ALDH1A1 (0.65) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL31690791 | 0.79 | ALDH1A1 (0.61) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL10389866 | 0.78 | OPRM1 (0.67) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL7504527 | 0.78 | ALDH1A1 (0.60) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL31557718 | 0.78 | OPRM1 (0.64) | ALDH1A1OPRD1OPRK1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| EP-1513836-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | ALDH1A1 509/4885OPRD1 71/4885OPRK1 172/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | ALDH1A1 445/4885OPRD1 47/4885OPRK1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.